Strand is a clinical-stage biotechnology company with a pipeline of breakthrough mRNA therapeutics for cancers and autoimmune diseases.
We’re solving the biggest problems in genetic medicine to build plug-and-play delivery systems that bring therapies to vastly more patients and indications.
Genetic medicines could cure humanity’s most challenging diseases, but only if we can deliver therapeutics safely, to the right tissues, anywhere in the body.
At baseline, drugs need to reach their targets: lipid nanoparticles (LNPs) need to direct mRNA to the right cells. But most genetic medicines can only reach the liver.
We engineer LNPs for high on-target tissue delivery throughout the body.
Our novel SignalPath LNP technology brings payloads to tumors, immune cells, and beyond.
Creating targeted mRNA isn’t enough. Some payloads inevitably reach off-target cells and create toxicity risks.
We’ve pioneered microRNA-sensing technology that enables us to encrypt mRNA, so payloads express in target tissues, but deactivate in off-target tissues.
SignalLock RNA enables unprecedented selectivity that makes mRNA therapies safe enough for widespread use.
Combined with the targeting of SignalPath LNPs, SignalLock RNA enables systemic delivery in a standard healthcare setting.
When medicines reach targets, they need to be strong enough for patient benefit. mRNA therapeutics have struggled with poor potency and durability.
We’re expanding the mRNA toolbox with potent, durable self-replicating and circular RNA.
Genetic medicines could cure humanity’s most challenging diseases, but only if we can deliver therapeutics safely, to the right tissues, anywhere in the body.
At baseline, drugs need to reach their targets: lipid nanoparticles (LNPs) need to direct mRNA to the right cells. But most genetic medicines can only reach the liver.
We engineer LNPs for high on-target tissue delivery throughout the body.
Our novel SignalPath LNP technology brings payloads to tumors, immune cells, and beyond.
Creating targeted mRNA isn’t enough. Some payloads inevitably reach off-target cells and create toxicity risks.
We’ve pioneered microRNA-sensing technology that enables us to encrypt mRNA, so payloads express in target tissues, but deactivate in off-target tissues.
SignalLock RNA enables unprecedented selectivity that makes mRNA therapies safe enough for widespread use.
Combined with the targeting of SignalPath LNPs, SignalLock RNA enables systemic delivery in a standard healthcare setting.
When medicines reach targets, they need to be strong enough for patient benefit. mRNA therapeutics have struggled with poor potency and durability.
We’re expanding the mRNA toolbox with potent, durable self-replicating and circular RNA.
.jpg)
Our solid tumor program is showing complete patient responses with our first drug, STX-001, via intratumoral injection.
As these technologies evolve we’ll push beyond solid tumors with STX-005, a pioneering approach to developing in vivo CAR T therapies for autoimmune diseases and blood cancers.
Our solid tumor program is showing complete patient responses with our first drug, STX-001, via intratumoral injection.
As these technologies evolve we’ll push beyond solid tumors with STX-005, a pioneering approach to developing in vivo CAR T therapies for autoimmune diseases and blood cancers.
We stand on the shoulders of giants in genetic medicine. Our interdisciplinary team is dedicated to pushing the genetic medicine revolution further, across vastly more indications and patient populations.
To get there, we need more bold, passionate thinkers hungry for cures.
